AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14533665 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 5 mg/d
Number of subjects: 22
Study 14533665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14533665 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22
Study 14533665 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 22
Study 10928575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40
Study 10928575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9635271 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA) - loading dose 15 mg/kg, continuous infusion 10 mg/kg per hour for 6 hours
Number of subjects: 59
Study 9635271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - loading dose 15 mg/kg, continuous infusion 1 mg/kg per hour for 6 hours
Number of subjects: 59
Study 9635271 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion for 6 hours
Number of subjects: 59
Study 1392155 — intervention group
Group type: EXPERIMENTAL
Intervention: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group A: vindesine (2.5 mg/m2 day 1 and 8), mitoxantrone (12 mg/m2/day) every 4 weeks, mitomycin C (8 mg/m2) every 8 weeks
Number of subjects: 103
Study 1392155 — intervention group
Group type: EXPERIMENTAL
Intervention: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group B: vindesine (2.5 mg/m2), mitoxantrone (12 mg/m2) every 3 weeks on day 1, mitomycin C (8 mg/m2) every 6 weeks
Number of subjects: 103
Study 3912735 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz rays (4 Gy applied on 6 occasions at intervals of 1 week)
Number of subjects: 16
Study 3912735 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control side)
Number of subjects: 16
Study 29976505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated at sites with major RTQA violations (n=86)
Number of subjects: 554
Study 29976505 — intervention group
Group type: COMPARATOR
Intervention: Patients treated at sites without major violations
Number of subjects: 554
Study 26673433 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm)
Number of subjects: 506
Study 26673433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 25348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib
Number of subjects: 295
Study 25348000 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 295
Study 25348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib (HER2-positive tumors)
Number of subjects: 295
Study 25348000 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo (HER2-positive tumors)
Number of subjects: 295
Study 25348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib (HER2-normal tumors)
Number of subjects: 295
Study 25348000 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo (HER2-normal tumors)
Number of subjects: 295
Study 25348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for fulvestrant plus lapatinib
Number of subjects: 295
Study 25348000 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) for fulvestrant plus placebo
Number of subjects: 295
Study 21296903 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% discount on healthier foods
Number of subjects: 1104
Study 21296903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition education
Number of subjects: 1104
Study 21296903 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1104
Study 19741509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (ASA)
Number of subjects: 40
Study 19741509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 40
Study 19741509 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 40
Study 17196359 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeStopTherapy (SST)
Number of subjects: 225
Study 17196359 — intervention group
Group type: EXPERIMENTAL
Intervention: minimal intervention strategy for lung patients (LMIS)
Number of subjects: 225
Study 15040966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM) technique
Number of subjects: 14
Study 15040966 — intervention group
Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 14
Study 11228032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management with medication, physiotherapy, or bracing
Number of subjects: 0
Study 11228032 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg epirubicin in 50 mL normal saline immediately after TURBT
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg epirubicin in 50 mL normal saline 1-2 weeks after TURBT, repeated for 8 weeks and thereafter monthly for one year
Number of subjects: 168
Study 9158511 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy after TURBT (control group)
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose epirubicin
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with epirubicin
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 168
Study 9158511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated groups
Number of subjects: 168
Study 8119091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol) applied as a spray (1 ml) at the end of the operation
Number of subjects: 30
Study 8119091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 30
Study 3116982 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during nitrendipine treatment
Number of subjects: 0
Study 3116982 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during placebo
Number of subjects: 0
Study 352705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine 600 mg daily for 1 week
Number of subjects: 10
Study 352705 — intervention group
Group type: COMPARATOR
Intervention: No active drug (placebo)
Number of subjects: 10
Study 31608711 — intervention group
Group type: EXPERIMENTAL
Intervention: creatine 30 g/day (CRE)
Number of subjects: 60
Study 31608711 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen 40 mg/day (T40)
Number of subjects: 60
Study 31608711 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen 80 mg/day (T80)
Number of subjects: 60
Study 31608711 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 31338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 8
Study 31338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 8
Study 31338198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28032568 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day intensive preoperative pulmonary rehabilitation (PR)
Number of subjects: 60
Study 28032568 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative respiratory management (NPR)
Number of subjects: 60
Study 25351788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g kg(‐1) ammonia chloride (ACD)
Number of subjects: 8
Study 25351788 — intervention group
Group type: COMPARATOR
Intervention: 0.3 g kg(‐1) calcium carbonate (PLA)
Number of subjects: 8
Study 25351788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g kg(‐1) sodium bicarbonate (ALK)
Number of subjects: 8
Study 23962878 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) programme, high compliance tertile
Number of subjects: 4556
Study 23962878 — intervention group
Group type: COMPARATOR
Intervention: Control group (low compliance tertile)
Number of subjects: 4556
Study 21337251 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment (combined sauna, cold water immersion, and jacuzzi) after the first match for post-PHV players
Number of subjects: 28
Study 21337251 — intervention group
Group type: COMPARATOR
Intervention: No specific between-match recovery intervention (control) for post-PHV players
Number of subjects: 28
Study 19767791 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg diazepam (HIGH)
Number of subjects: 15
Study 19767791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (LOW)
Number of subjects: 15
Study 19767791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 15
Study 18212651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 66
Study 18212651 — intervention group
Group type: COMPARATOR
Intervention: Russell‐Taylor Reconstruction Nail (RTRN)
Number of subjects: 66
Study 15476225 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtalar-strapped insole
Number of subjects: 66
Study 15476225 — intervention group
Group type: COMPARATOR
Intervention: Traditional wedged insole
Number of subjects: 66
Study 11532885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RT tasks
Number of subjects: 0
Study 11532885 — intervention group
Group type: COMPARATOR
Intervention: Single RT tasks
Number of subjects: 0
Study 11532885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RT tasks that interfere
Number of subjects: 0
Study 9575584 — intervention group
Group type: EXPERIMENTAL
Intervention: Salben (powder for inhalations)
Number of subjects: 112
Study 9575584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium bensoate)
Number of subjects: 112
Study 8160726 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous ambulatory monitoring of esophageal pH and motility
Number of subjects: 0
Study 8160726 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation of an esophageal balloon
Number of subjects: 0
Study 8160726 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter manipulation in the right atrium
Number of subjects: 0
Study 8160726 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation and treatment of chest pain in patients with angiographically normal coronary arteries
Number of subjects: 0
Study 2975290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12
Study 2975290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12
Study 2975290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg
Number of subjects: 12
Study 2975290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2975290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (all doses)
Number of subjects: 12
Study 30062393 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral position
Number of subjects: 30
Study 30062393 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamrock position
Number of subjects: 30
Study 30062393 — intervention group
Group type: COMPARATOR
Intervention: Medial position
Number of subjects: 30
Study 28965097 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective laryngeal reinnervation
Number of subjects: 30
Study 28965097 — intervention group
Group type: COMPARATOR
Intervention: Type I thyroplasty
Number of subjects: 30
Study 25070400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal additional IOL
Number of subjects: 32
Study 23645534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with temozolomide or irinotecan
Number of subjects: 13
Study 21514988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 mcg
Number of subjects: 64
Study 21514988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20mg vitamin B(6))
Number of subjects: 64
Study 18068887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (self-etch adhesive)
Number of subjects: 50
Study 18068887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond 1 XT (total-etch adhesive)
Number of subjects: 50
Study 18068887 — intervention group
Group type: COMPARATOR
Intervention: Both adhesives (self-etch and total-etch)
Number of subjects: 50
Study 17351746 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Afimoxifene gel
Number of subjects: 0
Study 17351746 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 17351746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg Afimoxifene gel
Number of subjects: 0
Study 14986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype resistance testing (PT arm)
Number of subjects: 0
Study 14986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype resistance testing (GT arm)
Number of subjects: 0
Study 14986258 — intervention group
Group type: COMPARATOR
Intervention: No access to either test (VB arm)
Number of subjects: 0
Study 11258646 — intervention group
Group type: EXPERIMENTAL
Intervention: IAT(3/2) test procedure (3 min step duration, 2 km/h increment until volitional exhaustion)
Number of subjects: 111
Study 11258646 — intervention group
Group type: COMPARATOR
Intervention: Retest or alternative test procedures (submaximal, preliminary exercise, 5 min step duration, 1 km/h increment)
Number of subjects: 111
Study 11258646 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate preliminary exercises (approximately 4 mmol/l lactate)
Number of subjects: 111
Study 11258646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of speed increment from 2 to 1 km/h
Number of subjects: 111
Study 9209165 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (JIB)
Number of subjects: 8
Study 9209165 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight control subjects
Number of subjects: 8
Study 7748304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin uptake inhibitors (SUI; e.g., citalopram, fluoxetine)
Number of subjects: 0
Study 7748304 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5‐HT1A receptor partial agonist)
Number of subjects: 0
Study 7748304 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP (5‐HT partial agonist)
Number of subjects: 0
Study 7748304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5‐HT3 antagonist, 0.5 mg/day)
Number of subjects: 0
Study 7748304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin uptake inhibitors (SUI) with brief psychosocial intervention
Number of subjects: 0
Study 3433871 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d. for 2 months
Number of subjects: 21
Study 31816053 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Internet Condition (MIC)
Number of subjects: 89
Study 31816053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Psychoeducation and Internet Condition (NPC)
Number of subjects: 89
Study 31816053 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 89
Study 31816053 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC/NPC (participants achieving clinically meaningful weight loss >2.5%)
Number of subjects: 89
Study 31816053 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC/NPC (participants)
Number of subjects: 89
Study 29535282 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Mandibular Exercise (AME) for 4 weeks, consisting of maximal mouth opening, lateral excursion, and protrusive movement, repeated ten times a day
Number of subjects: 62
Study 29535282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 26967654 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for trial preparation and conduct, including sensitisation meetings led by local leaders, involvement of Health Extension Workers, and use of local analogies for explaining randomisation.
Number of subjects: 94
Study 26967654 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intervention arm participants receiving small incentives to continue in the trial.
Number of subjects: 94
Study 25690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Community workshops promoting gender equity in reproductive health
Number of subjects: 0
Study 24331681 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial use of formula diet (FD)
Number of subjects: 229
Study 24331681 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-caloric diet (CD)
Number of subjects: 229
Study 19772689 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Lunch Box intervention
Number of subjects: 1294
Study 19127781 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (magnet pellets placed at both auricles, acupressure from day 3 to day 6)
Number of subjects: 98
Study 19127781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study 19127781 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 98
Study 16898002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) starting at 40 mg/m2, increased to 50 mg/m2 at level 2.
Number of subjects: 9
Study 16898002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) at dose level 1 (40 mg/m2).
Number of subjects: 9
Study 12743975 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, multimedia CD‐ROM
Number of subjects: 77
Study 12743975 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (self‐study module, brief lecture, demonstration, hands-on experience)
Number of subjects: 77
Study 10831272 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapeutic agents (IFN‐α and/or IL‐2)
Number of subjects: 0
Study 10831272 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 8781467 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicide-coated condoms
Number of subjects: 1233
Study 8781467 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of condom
Number of subjects: 1233
Study 8781467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse frequency
Number of subjects: 1233
Study 8781467 — intervention group
Group type: EXPERIMENTAL
Intervention: History of UTI
Number of subjects: 1233
Study 8781467 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicide-coated condom exposure
Number of subjects: 1233
Study 1351498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100
Study 1351498 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole
Number of subjects: 100
Study 6729769 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol + Sulfinpyrazone
Number of subjects: 0
Study 6729769 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol + Placebo
Number of subjects: 0
Study 6729769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone + Placebo
Number of subjects: 0
Study 6729769 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 31227528 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG, 1×10^10 colony forming units, twice daily
Number of subjects: 2650
Study 31227528 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identical appearing to the probiotic
Number of subjects: 2650
Study 31227528 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 2650
Study 31227528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2650
Study 29228205 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1506
Study 29228205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1506
Study 25733009 — intervention group
Group type: EXPERIMENTAL
Intervention: Running subcuticular closure (3-0 monofilament)
Number of subjects: 45
Study 25733009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical mattress closure (2-0 nylon)
Number of subjects: 45
Study 25733009 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staples
Number of subjects: 45
Study 25185574 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg alum‐adjuvanted OspA antigen
Number of subjects: 0
Study 25185574 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg alum‐adjuvanted OspA antigen
Number of subjects: 0
Study 25185574 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination (6 months or 9 to 12 months after first immunization)
Number of subjects: 0
Study 25185574 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg and 60 μg OspA antigen
Number of subjects: 0
Study 22709259 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 0
Study 22709259 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 19456845 — intervention group
Group type: EXPERIMENTAL
Intervention: Trucut biopsy (TCB)
Number of subjects: 77
Study 19456845 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration with high suction (FNAHS)
Number of subjects: 77
Study 17913669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid‐point 405
Number of subjects: 21000
Study 17913669 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM Premier 3000
Number of subjects: 21000
Study 17913669 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐STAT 1 (série 300)
Number of subjects: 21000
Study 17913669 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL 77
Number of subjects: 21000
Study 17913669 — intervention group
Group type: COMPARATOR
Intervention: i‐STAT (série 200)
Number of subjects: 21000
Study 17913669 — intervention group
Group type: COMPARATOR
Intervention: OMNI S
Number of subjects: 21000
Study 16103515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose at 2 mg x kg(‐1) x min(‐1)
Number of subjects: 14
Study 16103515 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9% (control group)
Number of subjects: 14